Dopaminergic Mechanisms in Depression and Mania

1. Allard P, Norlen M. Unchanged density of caudate nucleus dopamine uptake sites in depressed suicide victims. J. Neural Transms, 1997, 104, 1353-1360.

2. Ascher JA, Cole,JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, et al. Bupropion: A review of its mechanism of antidepressant activity. J. Clin. Psychiatr., 1995, 56, 395-401.

3. Ammar S, Martin,P.  Modelisation des effets des agonistes dopaminergiques en psychopharmacologie: vers une homothetie clinique et experimentale. Psychologie Francaise 1991, 36, 221-232.

4. Anderson IM, Cowen PJ. Prolactin response to the dopamine antagonist, metoclopramide, in depression. Biol. Psychiatr. 1991, 30, 313-316.

5. Ansseau M, von Frenckell R, Cerfontaine JL, Papart P, Franck G, Timset-Berthier M, Geenen V, Legros J-J. Neuroendocrine evaluation of catecholaminergic neurotransmission in mania. Psychiatr. Res. 1987, 22, 193-206.

6. Ansseau M, von Frenckell R, Cerfontaine JL, Papart P, Franck G, Timset-Berthier M, Geenen V, Legros J-J. Blunted response of growth hormone to clonidine and apomorphine in endogenous depression. Brit. J. Psychiatr. 1988, 153, 65-71.

7. Asherson P, Mant R, Williams N, Cardno A, Jones L, Murphy K, Collier DA, Nanko S, Craddock N, Morris S, Muir W, Blackwood B, McGuffin P, Owen MJ. A study of chromosome 4p markers and dopamine D5 receptor gene in schizophrenia and bipolar disorders. Mol. Psychiatr., 1998, 3, 310-320.

8. Ayd FJ Jr., Zohar J. Psychostimulant (amphetamine or methylphenidate) therapy for chronic and treatment-resistant depression. In: Zohar J, Belmaker RH, eds. Treating Resistant Depression. New York: PMA Corp., 1987, 343-355

9. Baxter LR, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, Gerner RH, Sumida RM. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch. Gen. Psychiatr. 1989, 46, 243-250.

10. Belmaker RH, Wald D. Haloperidol in normals. Brit. J. Psychiatr. 1977, 131, 222-223.

11. Beninger RL, Nakonechny PL. Dopamine D1-like receptors and molecular mechanisms of incentive learning. In: Beninger RJ, Paolomo T, Archer T (eds) Dopamine Disease States, 1996, Editorial CYM, Madrid, pp.407-431.

12. Benkert O, Brunder G, Wetzel H. Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression. Parmacopsychiatry 1992, 25, 254-260.

13. Bennett JP, Piercey,MF. Pramipexole - A New Kind of Dopamine Agonist for the Treatment of Parkinson’s Disease. J. Neurosci. Res, in press.

14. Bermanzohn PC, Siris G. Akinesia: A syndrome common to Parkinsonism, retarded depression and negative symptoms of schizophrenia. Compr. Psychiatr. 1992, 33, 221-232.

15. Borsini F, Meli A. The forced swimming test: Its contribution to the understanding of the mechanisms of action of antidepressants. In: Gessa GL, Serra G, eds. Dopamine and Mental Depression. Oxford: Pergamon Press, 1990, 63-76.

16.  Bowden C, Theodorou AE, Cheetham SC, Lowther S, Katona CL, Crompton MR & Horton RW Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res, 1997, 752, 227-233.

17.  Bowden C, Cheetham SC, Lowther S, Katona CL, Crompton MR & Horton RW. Reduced dopamine turnover in the basal ganglia of depressed suicides. Brain Res, 1997, 769, 135-140.

18.  Bowden C, Cheetham SC, Lowther S, Katona CL, Crompton MR & Horton RW. Dopamine uptake sites, labelled with [3H]GBR12935, in brain samples from depressed suicides and controls. Eur. Neuropsychopharmacol., 1997, 7, 247-252.

19. Boyer P, Davila M, Schaub C, Nassiet J. Growth hormone response to clonidine stimulation in depressive states. Part. I. Psychiatrie et Psychobiologie 1986, 1, 189-195.

20. Brown AS, Gershon S. Dopamine and depression J. Neural Transm. [Gen. Sect.] 1993, 91, 75-109.

21. Brown RG, MacCarthy B, Gotham A-M, Der GJ, Marsden CD. Depression and disability in Parkinson's disease: A follow-up of 132 cases. Psychol. Med. 1988, 18, 49-55.

22. Byerley W, Leppert M, O'Connell P, Mellon C, Holik J, Lubbers A, Reimherr F, Jenson S, Holl K, Wender P, Grandy D, Litt M, Lalouel J-M, Civeli O, White R. D2 dopamine receptor gene not linked to manic-depression in three families. Psychiatr. Genet. 1990, 1, 55-62.

23. Cantello R, Aguggia M, Gilli M, Delsedime M, Chiardo Cutin I, Riccio A, Mutani R. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse. J. Neurol. Neurosurg. Psychiatr. 1989, 52, 724-731.

24. Carboni E, Tanda GL, Frau R, Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex. Evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 1990, 55, 1067-1070.

25. Cervo L, Samanin R. Repeated treatment with imipramine and amitriptyline reduces the immobility of rats in the swimming test by enhancing dopamine mechanisms in the nucleus accumbens. J. Pharm. Pharmacol. 1988, 40, 155-156.

26. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: A review and reconceptualization.Am. J. Psychiatr. 1991, 148, 1474-1486.

27.  De Montis MG, Devoto P, Gessa GL, Porcella A, Serra G, Tagliamonte A. Possible role of DA receptors in the mechanism of action of antidepressants. In: Gessa GL, Serra G, eds. Dopamine and Mental Depression. Oxford: Pergamon Press, 1990, 147-157.

28. Del Zompo M, Boccheta A, Bernardi F, Corsini GU. Clinical evidence for a role of dopaminergic system in depressive syndromes. In: Gessa GL, Serra G, eds. Dopamine and Mental Depression. Oxford: Pergamon Press, 1990, 177-184.

29. Delina-Stula A, Radeke E, van Riezen H. Enhanced functional responsiveness of the dopaminergic system: The mechanism of anti-immobility effects of antidepressants in the behavioural despair test in the rat. Neuropharmacology 1988, 27, 943-947.

30. Depue RA. Arbisi P, Krauss S, Iacono WG, Leon A, Muir R, Allen J. Seasonal independence of low prolactin concentration and high spontaneous eye blink rates in unipolar and bipolar II seasonal affective disorder. Arch. Gen. Psychiatr. 1990, 47, 356-364.

31. Depue RA, Arbisi P, Spoont MR, Krauss S, Leon A, Ainsworth B. Seasonal and mood independence of low basal prolactin secretion in premenopausal women with seasonal affective disorder. Am. J. Psychiatr. 1989, 146, 989-995.

32. D'haenen H, Bossuyt A. Dopamine D2 receptors in the brain measured with SPECT. Biol. Psychiatr. 1994, 15, 128-132.

33. Di Chiara G, Tanda G, Frau R, Carboni E. On the preferential release of dopamine in the nucleus accumbens by amphetamine: further evidence obtained by vertically implanted concentric probes. Psychopharmacology 1993, 112, 398-402.

34. Dziedzicka-Wasylewska,M., Willner,P. & Papp,M. Changes in dopamine receptor mRNA expression following chronic mild stress and chronic antidepressant treatment. Behavioural Pharmacology, 1997, 8, 607-618.

35. Ebert D, Albert R, Hammon G, Strasser B, May A, Merz A. Eye-blink rates and depression. Is the antidepressant effect of sleep deprivation mediated by the dopamine system? Neuropsychopharmacology, 1996, 15, 332-339.

36. Ebert D, Feistel H, Loew T & Priner A. Dopamine and depression: Striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Pschopharmacology, 1996, 126, 91-94.

37. Ebstein RP, Nemanov L, Klotz I, Gritsenko I, Belmaker RH. Additional evidence for an association between the dopamine D4 receptor (DRD4) exon III repeat polymorphism and the hujan personality trait of Novelty Seeking. Mol. Psychiatr. 2, 472-477.

38. Egeland JA, Gerhard DS, Pauls DL, Sussex JN, Kidd KK, Allen CR, Hostetter AM, Housman DE. Bipolar affective disorders linked to DNA markers on chromosome 11. Nature, 1987, 325, 783-787.

39. Fawcett J, Simonopoulos V. Dextroamphetamine response as a possible predictor of improvement with tricyclic therapy in depression. Arch. Gen. Psychiatr. 1971, 25, 247-255.

40. Fibiger HC. The dopamine hypotheses of schizophrenia and depression: Contradictions and speculations. In: Willner P, Scheel-Kruger J, eds. The Mesolimbic Dopamine System: From Motivation to Action. Chichester: John Wiley and Sons, 1991, 615-637.

41. Fryer JD, Lukas RJ Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. 1999, 288, 88-92.

42. Gjerris A, Werdelin L, Rafaelson OJ, Alling C, Christensen NJ. CSF dopamine increased in depression: CSF dopamine, noradrenaline and their metabolites in depressed patients and in controls. J. Affect. Disord. 1987, 13, 279-286.

43. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology 1984, 34, 1092-1094.

44. Gomez-Casero E, Perez de Castro I, Saiz-Ruiz J, Llinares C, Fernandez-Piqueras J. No association between particular DRD3 and DAT gene polymorphisms and manic-depressive illness in a Spanish sample. Psychiatr. Genet, 1996, 6, 209-212.

45. Goodwin FK, Ebert MH, Bunney WE. Mental effects of reserpine in man: A review. In: Shader RI, ed. Psychiatric Complications of Medical Drugs. New York: Raven Press, 1972, 73-101.

46. Goodwin FK, Sack RL. Central dopamine function in affective illness: evidence from precursors, enzyme inhibitors, and studies of central dopamine turnover. In: Usdin E, ed. Neuropsychopharmacology of Monoamines and their Regulatory Enzymes. New York: Raven Press,  1974, 261-279.

47. Guze BH, Barrio JC. The etiology of depression in Parkinson's disease patients. Psychosomatics 1991, 32, 390-394.

48. Gwirtsman HE, Guze BH. Amphetamine, but not methylphenidate, predicts antidepressant response. J. Clin. Psychopharmacol. 1989, 9, 453.

49. Harrow M, Yonan CA, Sands JR, Marengo J. Depression in schizophrenia: Are neuroleptics, akinesia, or anhedonia involved. Schizophr. Bull., 1994, 20, 327-338.

50. Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, Glover DP, Hurt RD. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Brit. J. Psychiatr. 174, 173-178.

51. Holmes DS, Brynjolfsson J, Brett P, Curtis D, Petursson H, Sherrington R, Gurling H. No evidence for a susceptibility locus predisposing to manic depression in the region of the dopamine (D2) receptor gene. Brit. J. Psychiatr. 1991, 158, 635-641.

52. Jacobs D, Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol. Med. 1988, 16, 323-329

53. Jeste DV, Lohr JB, Goodwin FK. Neuroanatomical studies of major affective disorders: A review and suggestions for future research. Brit. J. Psychiatr. 1988, 153, 444-59.

54. Jimerson DC. Role of dopamine mechanisms in the affective disorders. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987, 515-511.

55. Jouvent R, Abensour P, Bonnet AM, Widlocher D, Ajid Y, Lhermitte F. Antiparkinson and antidepressant effects of high doses of bromocriptine. J. Affect. Disord. 1983, 5, 141-145

56. King RJ, Mefford IN, Wang C, Murchison A, Caligari EJ, Berger PA. CSF dopamine levels correlate with extraversion in depressed patients. Psychiatr. Res. 1986, 19, 305-310.

57. Kirkpatrick B, Buchanan RW. Anhedonia and the deficit syndrome of schizophrenia. Psychiatr. Res. 1990, 31, 25-30.

58. Larisch R, Klimke A, Vosberg H, Loffler S, Gaebel W & Muller-Gartner H-W. In vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulate gyrus in major depression. Neuroimage, 1997, 5,, 251-260.

59. Lecrubier,Y,  Boyer,P, Turjanski,S & Rein,W. Amisulpride versus imipramine and placebo in dysthymia and major depression. Journal of Affective Disorders, 1997 43, 95-103.

60. Lim LC, Nothen MM, Korner J, Rietschel M, Castle D, Hunt N, Proppling P, Murray R & Gill M. No evidence of association between dopamine D4 receptor variants and bipolar affective disorder. Am. J. Med. Genet. 54, 259-263.

61. Little KY. Amphetamine, but not methylphenidate, predicts antidepressant response. J. Clin. Psychopharmacol. 1988, 8, 177-183.

62. Maj J. Behavioral effects of antidepressant drugs given repeatedly on the dopaminergic system. In: Gessa GL, Serra G, eds. Dopamine and Mental Depression. Oxford: Pergamon Press, 1990, 139-146.

63. Maj J, Papp M, Skuza G, Bigajska K, Zazula M. The influence of repeated treatment with imipramine, (+)- and (-)-oxaprotiline on behavioural effects of dopamine D-1 and D-2 agonists. J. Neural Transm. 1989, 76, 29-38.

64. Maj,J, Dziedzicka-Wasylewska,M, Rogoz,R, Rogoz,Z & Skuza,G (1996) Antideprssant drugs given repeatedly change the biding of the dopamine D2 receptor agonist [3H]N-0437, to dopamine D2 receptors in the rat brain. European Journal of Pharmacology 23, 49-54.

65. Maj,J, Dziedzicka-Wasylewska,M, Rogoz,R & Rogoz,Z (1998) Effect if antidepressant drugs administered repeatedly on the dopamine D3 receptors in the rat brain. European Journal of Pharmacology 351, 31-37.

66. Manki H, Kanabe S, Muramatsu T, Higuchi S, Suzuki E, Matsushita S, Onon Y, Chiba H, Shintani F, Nakamura M, Yagi G, Asai M. Dopamine D2, D3 and D4 receptor and transporter gene polymorphisms and mood disorders. J. Affect. Disord, 1996, 40, 7-13.

67. Meltzer HY,  Kolakowska T, Fang VS, Fogg L, Robertson A, Lewine R, Strahilevitz M, Busch D. Growth hormone and prolactin response to apomorphine in schizophrenia and major affective disorders. Relation to duration of illness and affective symptoms. Arch. Gen. Psychiatr. 1984, 41, 512-519.

68. Mendlewicz J, Linkowski P, Kerkhofs M, Desmedt D, Goldstein J, Copinschi G, Van Cauter E. Diurnal hypersecretion of growth hormone in depression. J. Clin. Endocrinol. Metab. 1985, 60, 505-512.

69. Mitchell P, Selbie L, Waters B, Donald J, Vivero C, Tully M, Shine J. Exclusion of close linkage of bipolar disorder to dopamine D1 and D2 receptor gene markers. J. Affect. Disord. 1992, 25, 1-11

70. Mouret J, LeMoine P, Minuit M-P. Marqueurs polygraphiques, cliniques et therapeutiques des depressions dopamino-dependantes (DDD). Confront. Psychiatr., Special Issue, 430-437

71. Murphy DL. L-dopa, behavioral activation and psychopathology. Res. Publ. Ass. Res. Nerv. Ment. Dis. 1972, 50, 472-493.

72. Murray JB. Depression in Parkinson’s disease. J. Psychol., 1996, 130, 659-667

73. Nelson JC. The use of antipsychotic drugs in the treatment of depression. In: Zohar J, Belmaker RH, eds. Treating Resistant Depression. New York: PMA Corp., 1987, 131-146.

74. Nothen MM, Erdmann J, Korner J, Lanczik M, Fritze J, Fimmers R, Grandy DK, O'Dowd B, Propping P. Lack of association between dopamine D1 and D2 receptor genes and bipolar affective disorder. Am. J. Psychiatr. 1992, 149, 199-201.

75. Nowak G, Skolnick P, Paul IA. Downregulation of dopamine1 (D1) receptors is species-specific. Pharmaol. Biochem. Behav. 1991, 39, 769-771.

76. Nurnberger JJ Jr., Gershon ES, Simmons S, Ebert M, Kessler LR, Dibble ED, Jimerson SS, Brown GM, Gold P, Jimerson DC, Guroff JJ, Storch FI. Behavioral, biochemical and neurochemical responses to amphetamine in normal twins and 'well-state' bipolar patients. Psychoneuroendocrinology 1982, 7, 163-176.

77. Nurnberger JJ Jr., Simmons-Alling S, Kessler L, Jimerson S, Schreiber J, Hollander E, Tamminga CA, Suzan Nadi N, Goldstein DS, Gershon ES. Separate mechanisms for behavioral, cardiovascular and hormonal responses to dextroamphetamine in man. Psychopharmacology 1984, 84, 200-204

78. Papp M, Klimek V, Willner P.Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology 1994, 115, 441-446.

79. Perry EK.  Cortical neurotransmitter chemistry in Alzheimer's disease. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987, 887-895.

80. Pitchot W, Ansseau M, Gonzalez Moreno A, Hansenne M, von Frenckell R. Dopaminergic function in panic disorder: Comparison with major and minor depression. Biol. Psychiatr. 1992, 32, 1004-1011.

81. Pitchot W, Hansenne M, Gonzalez Moreno A, Ansseau M. Suicidal behavior and growth hormone response to apomorphine test. Biol. Psychiatr. 1992, 31, 1213-1219.

82. Pitchot W, Hansenne M, Gonzalez Moreno A, von Frenckell R, Ansseau M. Psychopathological correlates of dopaminergic disturbances in major depression. Neuropsychobiology 1990, 24, 169-172.

83. Pogue-Geile M, Ferrell R, Deka R, Debski T, Manuck S. Human novelty-seeking personality traits and dopamine D4 receptor polymorphisms: A twin and genetic association study. Am. J. Med. Genet. 1998, 81, 44-48.

84. Post RM, Kotin J, Goodwin FK, Gordon E. Psychomotor activity and cerebrospinal fluid metabolites in affective illness. Am. J. Psychiatr. 1973, 130, 67-72.

85. Post RM, Weiss SRB, Pert A. Animal models of mania. In: Willner P, Scheel-Kruger J, eds. The Mesolimbic Dopamine System: From Motivation to Action. Chichester: John Wiley and Sons, 1991, 443-472.

86. Przegalinski E, Budziszewska B, Blaszcztnska E. Repeated treatment with antidepressant drugs and/or electroconvulsive shock (ECS) does not affect the quinpirole-induced elevation of serum corticosterone concentration in rats. J. Psychopharmacol. 1990, 4, 198-203.

87. Pulverenti L, Samanin R. Antagonism by dopamine, but not noradrenaline receptor blockers of the anti-immobility activity of desipramine after different treatment schedules in the rat. Pharmacol.Res.Comm. 1986, 18, 73-80.

88. Rampello L, Nicoletti G, Raffaele R. Dopaminergic hypothesis for retarded depression: A symptom profile for predicting therapeutical responses. Acta Psychiatr. Scand. 1991, 84, 552-554.

89. Randrup A, Munkvad I, Fog R, Gerlach J, Molander L, Kjellberg B, Scheel-Kruger J. Mania, depression and brain dopamine. In: Essman WB, Valzelli L, eds. Current Developments in Psychopharmacology (Vol.2). New York: Spectrum Press, 1975, 206-248.

90. Reddy PL, Khanna S, Subhash MN, Channabasavanna SM, Sridhara Rama Rao BS. CSF amine metabolites in depression. Biol. Psychiatr. 1992, 31, 112-118.

91. Rietschel M, Nothen MM, Lannfelt L, Sokoloff P, Schwartz JC, Lanczik M, Fritze J, Cichon S, Fimmers R, Korner J, Moller HJ, Propping P. A serine to glycine substitution at position 9 in the extracellular N-terminal part of the dopamine D3 receptor protein: No role in genetic predisposition to bipolar affective disorder. Psychiatr. Res. 1993, 46, 253-259.

92. Robertson MM, Trimble MR. Neuroleptics as antidepressants. Neuropharmacology 1981, 20, 1335-1336.

93. Roy A, Karoum F, Pollack S. Marked reduction in indexes of dopamine transmission among patients with depression who attempt suicide. Arch. Gen. Psychiatr. 1992, 49, 447-450.

94. Roy A, Pickar D, Linnoila M, Doran AR, Ninan P, Paul SM. Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatr. Res. 1985, 15, 281-290

95. Scavone C, Aizenstein ML, De Lucia R, Da Silva Planeta C. Chronic imipramine administration reduces apomorphine inhibitory effects. Eur. J. Pharmacol. 1986, 132, 263-267.

96. Schatzberg AF, Rothschild AJ. The roles of glucocorticoid and dopaminergic systems in delusional (psychotic) depression. Ann. N. Y. Acad. Sci. 1988, 537, 462-471.

97. Serra G, Argiolas A, Fadda F, Melis MR, Gessa GL. Chronic treatment with antidepressants prevents the inhibitory effect of small doses of antidepressants on dopamine synthesis and motor activity. Life Sci. 1979, 25, 415-424.

98. Serra G, Collu M, D'Aquila PS, de Montis GM, Gessa GL. Possible role of dopamine D1 receptor in the behavioural supersensitivity to dopamine agonists induced by chronic treatment with antidepressants. Brain Res. 1990, 527, 234-243.

99. Serra G, Forgione A, D'Aquila PS, Collu M, Fratta W, Gessa GL. Possible mechanism of antidepressant effect of L-sulpiride. Clin. Neuropharmacol. 1990, 13 Suppl. 1, S76-S83.

100. Serretti A, Macciardi F, Verga M, Cusin C, Pedrini S, Smeraldi E. Tyrosine hydroxylase gene associated with depressive symptomatology in mood disorder. Am J. Med. Genet, 1998, 81, 127-130.

101. Shah PJ, Ogilvie AD, Goodwin GM & Ebmeier KP. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol. Med., 1997, 27, 1247-1256.

102. Shaikh S, Ball D, Craddock N, Castle D, Hunt N, Mant R, Owen M, Collier D, Gill M.The dopamine D3 receptor gene: No association with bipolar affective disorder. J. Med. Genet. 1993, 30, 308-309.

103. Shively CA, Grant KA, Ehrenkaufer RL, Mach RH, Nader MA. Social stress, depression, and brain dopamine in female cynomolgous monkeys. Ann. N.Y. Acad. Sci., 1997, 807, 574-577.

104. Siever LJ, Uhde TW. New studies and perspectives on the noradrenergic receptor system in depression: Effects of the alpha2-adrenergic agonist clonidine. Biol. Psychiatr. 1984, 19, 131-156.

105. Silverstone T. Response to bromocriptine distinguishes bipolar from unipolar depression. Lancet 1984, 1, 903-904.

106. Siris S. Diagnosis of secondary depression in schizophrenia. Implications for DSM-IV. Schizophr. Bull. 1991, 17, 75-98.

107. Stewart J, Rajabi H. Initial increases in extracellular dopamine in the ventral tegmental area provide a mechanism for the development of desipramine-induced sensitization within the midbrain dopamine system. Synapse, 1996, 23, 258-264.

108. Suhara T, Nakayama K, Inoue O, Fukuda H, Shimizu M, Mori A, Tateno Y. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology 1992, 106, 14-18.

109. Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA & Meltzer HY. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res, 1995, 681, 109-116.

110. Taylor AE, Saint-Cyr JA. Depression in Parkinson's disease: Reconciling physiological and psychological perspectives. Neuropsychiatr. Pract. Opin. 1990, 2, 92-98.

111. Towell A, Willner P, Muscat R. Behavioural evidence for autoreceptor subsensitivity in the mesolimbic dopamine system during withdrawal from antidepressant drugs. Psychopharmacology 1986, 90, 64-71.

112. Van Praag HM, Korf J. Central monoamine deficiency in depression: Causative or secondary phenomenon. Pharmacopsychiatry 1975, 8, 321-326.

113. Van Praag HM, Korf J, Lakke JPWF, Schut T. Dopamine metabolism in depression, psychoses, and Parkinson's disease: The problem of specificity of biological variables in behavior disorders. Psychol. Med. 1975, 5, 138-146.

114. Willner P. Dopamine and depression: A review of recent evidence. Brain Res. Rev. 1983, 6, 211-246.

115. Willner P. Sensitization to antidepressant drugs. In: Emmett-Oglesby MV, Goudie AJ, eds. Psychoactive drugs: Tolerance and Sensitization. Clifton, N.J.: Humana Press, 1989, 407-459. 

116. Willner P. The chronic mild stress procedure as an animal model of depression: Valid, reasonably reliable, and useful, 1997, Psychopharmacology 134, 371-377.

117. Willner P, Papp M. Animal models to detect antidepressants: Are new strategies necessary to detect new antidepressants? 1997, In Skolnick P (ed) Antidepressants: New Pharmacological Strategies, Humana, Totowa NJ,  pp.213-234.

118. Willner P, Scheel-Kruger J, eds. The Mesolimbic Dopamine System: From Motivation to Action. Chichester: John Wiley and Sons, 1991.

119. Wise RA. Neuroleptics and operant behaviour: The anhedonia hypothesis. Behav. Brain Sci. 1982, 5, 39-88.

120. Wolfe N, Katz DI, Albert ML, Almozlino A, Durso R, Smith MC, Volicer L. Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major depression, and Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 1990, 53, 915-917.

121. Wong DF, Wagner HN Jr., Pearlson G, Dannals RF, Links JM, Ravert HT, Wilson AA, Suneja S, Bjorvvinssen E, Kuhar MJ, Tune L. Dopamine receptor binding of C-11-3-N-methyl-spiperone in the caudate of schizophrenic and bipolar disorder: A preliminary report. Psychopharmacol. Bull. 1985, 21, 595-598.

122. Zebrowska-Lupina I, Ossowska G, Klenk-Majewska B. The influence of antidepressants on aggressive behavior in stressed rats: The role of dopamine. Pol. J. Pharmacol. Pharm. 1992, 44, 325-335.

Back to Chapter

published 2000